A compartment model for a sustained release preparation with zero-order release.
スポンサーリンク
概要
- 論文の詳細を見る
A compartment model with zero-order release in the gastrointestinal tract, first-order absorption to plasma and first-order elimination from plasma was examined in a series of studies on the clinical pharmacokinetics of BKU, a sustained release preparation of urapidil. The plasma levels of urapidil were measured for 24 hours after a single oral dosing of BKU to six healthy male volunteers, followed by the repeated dosing at each 12 hours for 6 days. On day 7, the plasma levels were again measured for 24 hours after a single dosing. For the expression by the formulation of this model, the reduced model wherein the absorption rate constant is equivalent to the elimination rate constant was taken into consideration to the ordinary model. The reduced model was applied to the cases in whom fitting of the ordinary model failed to apply due to no distinction in two rate constants. Time lag from dosing to initiation of zero-order release was also considered. A simplex method was used for model fitting and parameter estimation to the data of a single administration. Without consideration of time lag, the reduced model was fitted in three cases out of 6, while the ordinary model was fitted in the other 3 cases. With considera tion of time lag, the reduced model was fitted in only one case. Akaike's Information Criterion revealed that the incorporation of the time lag improved the fittings. Plasma levels of repeated dosing were simulated using the parameters estimated from the data of a single dosing and were revealed to be close to the observed levels except for one case. However, the meanings or interpretations of the estimated parameters were not necessarily valid in the model with or without time lag.
著者
-
海老原 昭夫
大分医科大学医学部臨床薬理学
-
海老原 昭夫
大分医科大学臨床薬理学教室
-
小池 勇一
大分医科大学臨床薬理学教室
-
小池 勇一
大分医科大学 医学部臨床薬理
-
西 次男
科研製薬 (株) 開発部統計解析グループ
-
丹治 昭司
科研製薬 (株) 東京研究所代謝研究室
関連論文
- 健常成人におけるバルプロ酸反復投与時の体内動態
- ヒスタミンH_2受容体遮断薬
- ID-23 バルプロ酸のTDM
- Dosage regimen for ranitidin in renal impairment. (2). Multiple oral dose studies.
- A compartment model for a sustained release preparation with zero-order release.
- Assessment of a simple method for acetylator phenotyping with caffeine.
- Polymorphous mode of caffeine metabolism in the Japanese poeple. On genotypes.
- Pharmacokinetics, pharmacodynamics, and safety of bevantolol, a new .BETA.1-selective .BETA.-adrenoceptor antagonist, in Japanese healthy volunteers.
- Clinical pharmacological studies on a new .BETA.1 selective .BETA.-blocker, bevantolol.
- Factors of Altered Drug Binding to Serum Proteins In Vivo: Studies with Valproic Acid.
- Binding parameters during repeated dosing of valproic acid in healthy adults.
- Population pharmacokinetics of theophylline in patients with infantile bronchial asthma.
- Clinical pharmacology of ibopamine. (1). Safety and pharmacological actions after single and multiple oral doses in Japanese healthy subjects.
- Pharmacokinetics of bunazosin in renal dysfunction children.
- Pharmacokinetics of beta-methyldigoxin.
- Clinical pharmacology of nitrendipine - Single- and multiple-dose study in Japanese healthy subjects.:Single- and Multiple-Dose Study in Japanese Healthy Subjects
- Pharmacokinetics of ketoprofen sustained-releasing preparation (RPY-001) in Japanese normal adult persons.
- Pharmacodynamic and pharmacological effects of nipradilol (K-351) in healthy volunteers. Comparison with propranolol.:Comparison with Propranolol
- Influence of beta-adrenergic blocking agent on the circadian rhythm of blood pressure in patients with essential hypertension.
- Clinical phase I studies of a new antiemetic drug, SN-307 (ondansetron).
- タイトル無し
- Pharmacokinetics of digoxin in patients with duchenne muscular dystrophy.
- Dosage regimen for ranitidine in renal impairment.
- Effect of premedication term and premedication dose of diltiazem on pharmacokinetics of nifedipine.
- Effect of diltiazem on pharmacokinetics of theophylline.
- Pharmacodynamics and pharmacological actions of MPC-1304, a Ca antagonist, in healthy adults.
- Effects of angiotensin II converting enzyme inhibitor enarapril on autonomic nervous system.
- Serum protein binding of valproic acid in epileptic patients under chronic monotherapy.
- Pharmacodynamic and pharmacological effects of MPC-1304, a new calcium channel blocker, in healthy subjects. Results of multiple oral administration.:Results of Multiple Oral Administration
- Effects of MPC-1304 on blood flow of the finger tip.
- Pharmacokinetics and pharmacodynamic effects of sustained release formulation of urapidil (BKU) in healthy subjects. Results of repeated oral administration.:Results of Repeated Oral Administration
- タイトル無し
- Effect of beta-blockers on circadian rhythm of blood pressure in patients with essential hypertension.
- Clinical pharmacology of ibopamine. (2). Pharmacokinetics after single and multiple oral administration in healthy Japanese subjects.
- Pharmacodynamic and pharmacological effects of MPC-1304, a new calcium channel blocker, in healthy subjects. Results of single oral administration.:Results of Single Oral Administration
- 医学教育の中に「臨床薬理学」をどのように組み込むか? -学生実習としての「臨床薬効評価」-
- TDM of valproic acid(VPA).Study of an optimum blood sampling time.
- Pharmacokinetirs of diltiazem in patients with paroxysmal supraventricular tachycardia.
- Various types of caffeine metabolism in Japanese people. Studies by urine per 2 hours.
- Valproic acid blood level prediction by population pharmacokinetics and Bayes estimation method.
- Diuretic and uricosuric effects of traxanox sodium in healthy subjects: Comparison with hydrochlorothiazide by multiple-dose study.
- Pharmacokinetic and pharmacological effects of urapidil in healthy volunteers. Comparative study with prazosin.:Comparative Study with Prazosin
- Chronopharmacological study of furosemide in human subjects.
- Pharmacokinetics of beta-methyldigoxin.
- タイトル無し
- タイトル無し
- Pharmacokinetic and pharmacological properties of doxazosin mesilate in Japanese healthy adult volunteers.
- Comparison between direct assay and separating assay of blood beta-methyldigoxin by fluorescent polarized immunoassay.
- タイトル無し
- タイトル無し
- タイトル無し